Olema Pharmaceuticals Stock Z Score
| OLMA Stock | USD 4.14 0.31 6.97% |
Olema | Z Score |
Olema Pharmaceuticals Company Z Score Analysis
Olema Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Olema Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Olema Pharmaceuticals is extremely important. It helps to project a fair market value of Olema Stock properly, considering its historical fundamentals such as Z Score. Since Olema Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Olema Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Olema Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
Based on the company's disclosures, Olema Pharmaceuticals has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Olema Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Olema Pharmaceuticals' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Olema Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Olema Pharmaceuticals by comparing valuation metrics of similar companies.Olema Pharmaceuticals is currently under evaluation in z score category among its peers.
Olema Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Olema Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Olema Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Olema Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Olema Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Olema Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Olema Pharmaceuticals' value.| Shares | State Street Corp | 2024-12-31 | 1.9 M | Citadel Advisors Llc | 2024-12-31 | 1.7 M | Venbio Select Advisor Llc | 2024-12-31 | 1.7 M | Candriam Luxembourg S.c.a. | 2024-12-31 | 1.6 M | Wellington Management Company Llp | 2024-12-31 | 1.5 M | Vivo Capital, Llc | 2024-12-31 | 1.5 M | Woodline Partners Lp | 2024-12-31 | 1.4 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.3 M | Balyasny Asset Management Llc | 2024-12-31 | 1.1 M | Bain Capital Life Sciences Investors, Llc | 2024-12-31 | 7.5 M | Paradigm Biocapital Advisors Lp | 2024-12-31 | 7.3 M |
Olema Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 118.06 M | ||||
| Shares Outstanding | 74.24 M | ||||
| Shares Owned By Insiders | 3.21 % | ||||
| Shares Owned By Institutions | 96.79 % | ||||
| Number Of Shares Shorted | 8.22 M | ||||
| Price To Book | 1.66 X | ||||
| EBITDA | (104.58 M) | ||||
| Net Income | (96.66 M) | ||||
| Cash And Equivalents | 240.71 M | ||||
| Cash Per Share | 6.01 X | ||||
| Total Debt | 2.42 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 19.75 X | ||||
| Book Value Per Share | 3.48 X | ||||
| Cash Flow From Operations | (83.73 M) | ||||
| Short Ratio | 8.99 X | ||||
| Earnings Per Share | (2.28) X | ||||
| Target Price | 28.0 | ||||
| Number Of Employees | 87 | ||||
| Beta | 2.12 | ||||
| Market Capitalization | 330.38 M | ||||
| Total Asset | 276.94 M | ||||
| Retained Earnings | (305.63 M) | ||||
| Working Capital | 244.89 M | ||||
| Net Asset | 276.94 M |
About Olema Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Olema Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Olema Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Olema Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Olema Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Olema Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Olema Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Olema Pharmaceuticals Stock:Check out Olema Pharmaceuticals Piotroski F Score and Olema Pharmaceuticals Valuation analysis. For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Olema Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.